UROLOGY RESIDENT SEMINAR SCHEDULE – 2023 July to December CanMeds = Medical Expert (ME), Professional (P), Communicator (Com), Scholar (Sc), Collaborator (Col), Leader (L), Health Advocate (HA)

D	TE	TIME	LOCATION	SESSION	CAMPBELL'S CHAPTERS/TOPICS	PRESENTER-	OBJECTIVES	ROYAL COLLEGE COMPETENCIES				
	112	TIVIE	LOCATION	TOPIC		FACILITATOR		NOTAL COLLEGE COMPETENCIES				
	4	7:00 am	BLOCK 1 - EVALUATION OF THE UROLOGIC PATIENT No Seminars: PGIs = Surgical Foundations Bootcamp (all day July 4-14, 2023) PGY2-5 = Protected time for research or personal/wellness to be used at the discretion of the individuial resident									
		-12:00 pm 7:00 am	m 1-No Seminars. 1-015 = Surgical Pointactions Booleanip (an any July 4-14, 2023) 1-012-3 = Protected time for research or personal wetness to be used at the discretion of the individual resident									
		-12:00 pm		*No Seminars: PC	51s = Surgical Foundations Bootcamp (all day July 4-14, 2025) PGI.	research or personal/wellness to be usea at the	aiscretion of the mainialual resident					
July	4.0	8:00 -10:00 am		Evaluation of the Urologic Patient, Part 1	Program Orientation: 8:00 am Chiefs only; 8:15 am (PGY1s plus PGY5s) 8:30 am (PGY1-3): History and Physical Exam (1); Testing and Imaging (2); Intraoperative Consult (19)	Dr. Wang	in Urology: iv Describe common intraoperative consults. v.	1.3.3 Normal physiologic and anatomic changes of the urinary tract during pregnancy, 2.2.1 Perform a focused physical exam and urological history, including past and present medical history relevant to the urological care of the patient; 2.2.6.7 Medical imaging; 2.2.3 Assess the patient's functional status and quality of life; 2.2.6.1 Biochemical studies; 2.2.6.2 Tumour markers; 2.3.6.3 Urine tests; 2.2.6.7.3 Radioisotope studies; 2.4.15. Urological disorders in pregnancy				
		10:30 -11:30 am	Urol Conf Rm SJHC		Resident Meeting with the Chiefs (mandatory PGY1-5)	B.Liu L.Stringer						
		8:00 -10:00 am	Zoom	Evaluation of the Urologic Patient, Part 2	Urologic Considerations in Pregnancy (18); Evaluation and Management of Hematuria (16); Lower Urinary Tract Catheterization (11)	Dr. Bjazevic J.Wong		2.2.1 Perform a focused physical exam and urological history, including past and present medical history relevant to the urological care of the patient; 2.2.3 Assess the patient's functional status and quality of life; 2.2.4 Assess peri-operative risk; 1.3.9 Principles of oncology as they apply to neoplasms of the adrenal gland, kidney, urothelium, prostate, testis, penis, and malignancies metastatic to the genitourinary tract; 2.2.6.1 Biochemical studies; 2.2.6.2 Tumour markers; 2.3.6.3 Urine tests; 2.2.6.2 Tweldical imaging; 2.4 Establish a patient centred management plan for patients with the following; 3.1.10. Diagnostic endoscopy of the upper and lower urinary tract.				
		7:00 am -12:00 pm										
August	8	7:00 am -12:00 pm	0 am *No Comingration DCVI 5 — Protected time for research or personal/feedbase to be used at the discovering of the individual worldowt									
		8:00 -10:00 am	Zoom	Fundamentals of Urologic Obstruction, Part 3	Mgmt of Upper Urinary Tract Obstruction (89) Fundamentals of Upper Urinary Tract Drainage (12)	Dr. Razvi D.Matti		2.2.1 Perform a focused physical exam and urological history, including past and present medical history relevant to the urological care of the patient; 2.2.6.7 Medical imaging; 2.2.6.1 Biochemical studies; 2.4.2. Obstructive disorders of the upper and lower urinary tract; 3.1.10. Diagnostic endoscopy of the upper and lower urinary tract; 3.1.11. Therapeutic endoscopy of the upper and lower urinary tract;				
BLOCK 2 - PROFESSIONALISM AND PATIENT SAFETY												
August		8:00 -10:00 am	Zoom	Urologic Care	Ethics and Informed Consent; Assessment of Urologic and Surgical Outcomes (6); Complications of Urologic Surgery (17) *include epi / critical appraisal	Dr. Pautler V.Turnbull		3.2 Obtain and document informed consent, explaining the risks and benefits of, and the rationale for, a proposed procedure or therapy				
⋖		7:00 am -12:00 pm		*No Seminars: PG	Y1-5 = Protected time for research or personal/wellness to be used at	the discretion of the indiv	iduial resident					
BLOCK 3 - FUNDAMENTALS OF UROLOGIC IMAGING												
September		8-10:00 am	Zoom	Embryology and Urological Imaging	UT Imaging: Basic Principles of CT, MRI, & Plain Film Imaging (3); Urinary Tract Imaging: Principles of urologic ultrasonography (4); Urinary Tract Imaging: Basic Principles of Nuclear Medicine (5)	Dr.P.Crivellaro and Dr.V.Kalia (GU Rad) B.Li		1.3.1 Embryology, and normal growth and development of the genitourinary tract; 1.3.2 Anatomy, physiology, and pathology of the genitourinary tract; 2.2.6.7 Medical imaging; 22.6.7.2. Ultrasonography of the kidney, bladder, prostate, and scrotal contents; 2.2.6.7.3 Radioisolope studies; 2.2.6.7.3.1. Renal scans; 2.2.6.7.3.3. Bone scan for staging of malignancy; 2.2.6.7.4 Computer tomography (CT) of the abdomen and pelvis, including CT urogram; 2.2.6.7.5 Magnetic resonance imaging (MRI) scanning of the urinary tract				
		10-12:00 noon	Zoom	Embryology and Urological Imaging	Embyrology of the GU Tract (20)	Dr. Dave H.Rotz		1.3.1 Embryology, and normal growth and development of the genitourinary tract; 1.3.2 Anatomy, physiology, and pathology of the genitourinary tract; 2.2.6.7 Medical imaging; 2.2.6.7.2 Ultrasonography of the kidney, bladder, prostate, and scrotal contents; 2.2.6.7.3 Radioisotope studies; 2.2.6.7.3.1. Renal scans; 2.2.6.7.3 Medical imaging; 2.2.6.7.2 Ultrasonography of maligrancy; 2.2.6.7.4 Computer tomography (CT) of the abdomen and pelvis, including CT urogram; 2.2.6.7.5 Magnetic resonance imaging (MRI) scanning of the urinary tract				
BLOCK 4 - PERIOPERATIVE MANAGEMENT OF THE UROLOGIC PATIENT												
Der		7:00-12:00 pm	MSB483 Med.Sci.Bldg Anatomy Lab, UWO	Perioperative Evaluation & Basics of Urologic Surgery	Principles of Urologic Surgery: Perioperative Care (8); Incisions and Access (9); Intraoperative Technical Decisions (10)	Dr.Huvnh		2.2.4 Assess peri-operative risk; 1.3.11 Principles of the therapeutic techniques used in urologic practice; 3.1.12. Laparoscopic surgery, including robot assisted laparoscopic surgery; 3.1.13. Abdominal/retroperitoneal surgery; 3.1.14. Pelvic surgery; 1.3.2 Anatomy, physiology, and pathology of the genitourinary tract				
September		am	Zoom	Minimally Invasive Surgery in Urology	Principles of Urologic Endoscopy (13); Fundamentals of Laparoscopic and Robotic Urologic Surgery (14); Basic Energy Modalities in Urologic Surgery (15); Radiation/Laser Safety	Dr. Bjazevic M.NejadMansouri		1.3.11 Principles of the therapeutic techniques used in urologic practice; 1.3.11.8. Laparoscopy; 3.1.10. Diagnostic endoscopy of the upper and lower urinary tract; 3.1.12. Laparoscopic surgery, including robot assisted laparoscopic surgery; 1.3.10. Biology and safety related to the use of radiation, laser and cytotoxic interventions				
	26	8:00-12:00 pm		*No Seminars: PG individuial residen	Y1-5 = Protected time for research or personal/wellness to be used at t	the discretion of the						

	BLOCK 5 - BASIC SCIENCES									
Oct.	3	8-10:00 am	Zoom	Immunology in Urological Oncology	Basic Principles of Immunology and immunotherapy in urologic oncology (61); Molecular Genetics & Cancer Biology (62)	Dr. Winquist (MedOnc) A.Gupta		1.3.9 Principles of oncology as they apply to necoplasms of the adrenal gland, kidney, urothelium, prostate, testis, penis, and malignancies metastatic to the genitourinary tract; 1.3.9.4 Treatment options including the role of surgery, hormonal therapy, radiation therapy, chemotherapy, and immunotherapy; 1.3.9.1 Risk factors, incidence and prevalence, genetic predisposition, and growth and dissemination patternsn, and prognostic variables; 1.3.11 Principles of the therapeutic techniques used in urologic practice; 1.3.11.7. Immunotherapy; 2.4.7. Neoplasms of the genitourinary tract: benign and malignant		
	BLOCK 6 - TESTIS									
October	10	8-10:00 am	Zoom	Neoplasms of the Testis	Surgery for Testicular Tumors (77); Laparoscopic and robotic- assisted retroperitoneal lymphadenectomy for testicular tumors (78)	Dr. Power C.MacLeod		1.3.9 Principles of oncology as they apply to neoplasms of the adrenal gland, kidney, urothelium, prostate, testis, penis, and malignancies metastatic to the genitourinary tract; 1.3.9.1 Risk factors, incidence and prevalence, genetic predisposition, and growth and dissemination pattersns, and prognostic variables; 1.3.9.2 Use of tumour markers for screening and surveillance; 1.3.9.3 Staging of neoplasms urins tumour-node-metastasis (TNM) staging system or other relavant classification system, and applicable predictive and prognostic indices; 1.3.9.4 Treatment options including the role of surgery, homomal therapy, radiation therapy, chemotherapy, and immunotherapy, 1.3.9.5 Principles of palliative and end-of-life care; 2.2.3 Assess theris functional status and quality of life; 2.2.4 Assess peri-operative risk; 2.2.6.1 Biochemical studies; 2.2.6.2 Tumour markers; 2.2.6.7 Medical imaging; 2.2.6.7.3 Radioisotope studies; 2.4.7. Neoplasms of the genitourinary tract: benign and malignant; 3.1.12. Laparoscopic surgery, including robot assisted laparoscopic surgery, 3.1.13. Abdominal/retroperitoneal surgery, 3.1.14. Pelvic surgery		
	17	8-12:00 pm	MSB483 Med.Sci.Bldg Anatomy Lab, UWO	Retroperitoneal Anatomy and Principles of Scrotal Sugery	Surgical, radiographic, and endoscopic anatomy of the retroperitoneum (75); Surgery of the scrotum and seminal vesicles (83)	T.Beveridge Dr. Wang W.Luke		3.1.13. Abdominal/retroperitoneal surgery; 1.3.2 Anatomy, physiology, and pathology of the genitourinary tract; 2.2.6.7 Medical imaging; 3.1.10. Diagnostic endoscopy of the upper and lower urinary tract; 3.1.11. Therapeutic endoscopy of the upper and lower urinary tract; 3.1.14. Pelvic surgery;		
						BLOCK 7 -	MALE GENITALIA			
October	24	8-10:00 am	Zoom	Neoplasms of the External Genitalia	Tumors of the penis (79): Tumors of the urethra (80)	Dr. Inman M.Smith		1.3.9 Principles of oncology as they apply to neoplasms of the adrenal gland, kidney, urothelium, prostate, testis, penis, and malignancies metastatic to the genilourinary tract; 1.3.9.1 Risk factors, incidence and prevalence, genetic predisposition, and growth and dissemination pattersns, and prognostic variables; 1.3.9.2 Use of tumour markers for screening and surveillance; 1.3.9.3 Staging of neoplasms urins tumour-node-metastasis (TMM) staging system or other relevant classification system, and applicable predictive and prognostic indices; 1.3.9.4 Treatment options including the role of surgery, hormonal therapy, radiation therapy, chemotherapy, and immunotherapy, 1.3.9.5 Principles of palliative and end-of-life care; 2.2.3 Assess the patient's functional status and quality of life; 2.2.4 Assess peri-operative risk; 2.2.6.7 Medical imaging; 3.1.14. Pelvic surgery, 3.1.10. Diagnostic endoscopy of the upper and lower urinary tract; 3.1.11. Therapeutic endoscopy of the upper and lower urinary tract; benign and malignant		
	31	8-12:00 pm		*No Seminars: PGY1-5 = Protected time for research or personal/wellness to be used at the discretion of the individuial resident						
Nov.	7	8-12:00 pm	MSB483 Med.Sci.Bldg Anatomy Lab, UWO	Principles of Inguinal Nodel Dissection	Inguinal node dissection (81)	T.Beveridge and Dr. Power H.Abed	ANATOMY LO: Extent of Fascia lata, Superficial and deep inguinal LN packets, LN of Cloquet, tributaries of great saphenous "to be revised"	1.3.2 Anatomy, physiology, and pathology of the genitourinary tract; 3.1.13. Abdominal/retroperitoneal surgery; 3.1.14. Pelvic surgery; 3.1.15. Genital surgery;		
					BLC	OCK 8 - RENAL/UPP	ER URINARY TRACT MASSES			
November	14	8-10:00 am	Zoom	Neoplasms of the Kidney	Benign Renal Tumors (96); Malignant Renal Tumors (97)	Dr. Sener D.Matti		1.3.9 Principles of oncology as they apply to neoplasms of the adrenal gland, kidney, urothelium, prostate, testis, penis, and malignancies metastatic to the genilourinary tract; 1.3.9.1 Risk factors, incidence and prevalence, genetic predisposition, and growth and dissemination pattersns, and prognostic variables; 1.3.9.2 Use of tumour markers for screening and surveillance; 1.3.9.3 Staging of neoplasms urins tumour-node-metastasis (TNM) staging system or other relavant classification system, and applicable predictive and prognostic indices; 1.3.9.4 Treatment options including the role of surgery, homomal therapy, radiation therapy, chemotherapy, and immunotherapy, 1.3.9.5 Principles of palliative and end-of-life care; 2.2.3 Assess theirs functional status and quality of life; 2.2.4 Assess peri-operative risk; 2.2.6.7 Medical imaging; 2.2.6.1 Biochemical studies; 2.2.6.2 Tumour markers; 2.4.7. Neoplasms of the genilourinary tract: benign and malignant		
Nove	21	8-12:00 pm	MSB483 Med.Sci.Bldg Anatomy Lab, UWO	Kidney and Ureteric Anatomy	Surgical, radiologic and endoscopic anatomy of the kidney and ureter (84)	T.Beveridge, Dr.Wang, Dr.Denstedt	ANATOMY LO: Open approach to the Ureter? Extraperitoneal vs transperitoneal? "To be revised"	1.3.2 Analomy, physiology, and pathology of the genitourinary tract; 2.2.6.7 Medical imaging; 3.1.10. Diagnostic endoscopy of the upper and lower urinary tract; 3.1.11. Therapeutic endoscopy of the upper and lower urinary tract;		
	28			*No Seminars: PG	YI-5 = Protected time for research or personal/wellness to be used at					
ļ	5	8-10:00 am	Zoom	Neoplasms of the Ureter and Retro- peritoneum	Urothelial tumors of the upper urinary tract & ureter (80); Retroperitoneal tumors (100); Surg Management of UUT Tumors (99)	Dr. Luke L.Stringer		1.3.9 Principles of oncology as they apply to neoplasms of the adrenal gland, kidney, urothelium, prostate, testis, penis, and malignancies metastatic to the genitourinary tract; 1.3.9.1 Risk factors, incidence and prevalence, genetic predisposition, and growth and dissemination pattersns, and prognostic variables; 1.3.9.2 Use of tumour markers for screening and suveillance; 1.3.9.3 Staging of neoplasms urins tumour-node-metastasis lystaging system or other relavant classification system, and applicable predictive and prognostic indices; 1.3.9.4 Treatment options including the role of surgery, hormonal therapy, radiation therapy, chemotherapy, and immunotherapy; 1.3.9.5 Principles of palliative and end-of-life care; 2.2.3 Assess the patient's functional status and quality of life; 2.4 Assess peri-operative risk; 2.6.7 Medical imanging; 2.2.6.1 Biochemical studies; 2.6.2 Tumour markers; 2.4.7. Neoplasms of the genitourinary tract: benign and malignant; 3.1.10. Diagnostic endoscopy of the upper and lower urinary tract; 3.1.11. Therapeutic endoscopy of the upper and lower urinary tract; 3.1.13. Abdominal/retroperitoneal surgery; 3.1.14. Pelvic surgery; 2.2.6.73. Radioisotope studies		
December	12	8-12:00 pm	MSB483 Med.Sci.Bldg Anatomy Lab, UWO	Principles of Renal Surgery	Open surgery of the kidney/Anatomy (101); Lap and robot surgery of the kidney (102)	T.Beveridge (Ethicon); Dr. Sener B.Liu		1.3.2 Anatomy, physiology, and pathology of the genitourinary tract; 3.1.13. Abdominal/retroperitoneal surgery; 3.1.14. Pelvic surgery; 3.1.12. Laparoscopic surgery, including robot assisted laparoscopic surgery; 3.1.2. Blood products and hemostatic agents;		
	19	8-10:00	Zoom	Advanced and Non-Surgical Treatment of Renal Neoplasms	Non-surgical focal therapy for renal tumors (103); Treatment of advanced renal cell Ca (104)	Dr. Correa (RadOnc) H.Rotz		1.3.9 Principles of oncology as they apply to neoplasms of the adrenal gland, kidney, urothelium, prostate, testis, penis, and malignancies metastatic to the genitourinary tract; 1.3.9.3 Staging of neoplasms urins turnour-node-metastasis (TNM) staging system or other relevant classification system, and applicable predictive and prognostic indices; 1.3.9.4 Treatment options including the role of surgery, hornounal therapy, radiation therapy, chemotherapy, and immunotherapy; 1.3.9.5 Principles of pallatitive and end-of-life care; 2.4.7. Neoplasms of the genitourinary tract bening nat malignant; 2.2.3 Assess the patients functional status and quality of life; 2.24 Assess per-operative risk; 2.2.6.7 Medical imaging; 2.2.6.1 Biochemical studies; 2.2.6.2 Turnour markers; 1.3.8 Pharmacology as it retales to the pharmacokinetics, pharmacodynamics, mechanisms or action, routes of delivery and elimination, and adverse effects of medications used to treat urology conditions; 1.3.1.7. Immunotherapy; 1.3.1.1.1. Radiofrequency ablation; 2.2.6.7.3 Radioisotope studies; 3.1.6. Radiofrequency ablation/ cryotherapy		